REVEAL 2.0 风险评分预测肺动脉高压生存及与 ESC/ERS 策略比较
基于美国 REVEAL 登记中生存≥1 年的肺动脉高压亚组,更新并重新评估 REVEAL 2.0 风险计算器的分值、切点与新变量。REVEAL 2.0 区分度与原计算器相近(c 统计量 0.76 对 0.74),三分类评分区分度(c 统计量 0.73)优于 COMPERA(0.62)与 FPHR(0.64)。
要点
- REVEAL 2.0 对肺动脉高压患者 12 个月生存具有良好区分度,c 统计量为 0.76。
- 三分类 REVEAL 2.0 评分区分度优于 COMPERA 与 FPHR 风险评估策略。
- COMPERA 与 FPHR 相较 REVEAL 2.0 存在风险低估与高估,需外部验证后用于治疗决策。
核心结论
- REVEAL 2.0 在 REVEAL 登记患者中的风险区分度优于 COMPERA 与 FPHR 风险评估策略。
- 经外部验证后,REVEAL 2.0 可帮助临床医生与患者依据个体风险特征做出知情治疗决策。
研究设计与样本
- 分析美国 REVEAL 登记中入组后生存≥1 年的亚组人群,该时点作为本队列基线。
- 重新评估 REVEAL 2.0 的分值与切点并评价新变量,用 Kaplan-Meier 法估计基线后 12 个月生存,以 c 统计量量化区分度。
- 将 REVEAL 2.0 与 COMPERA、FPHR 风险策略比较死亡估计与区分度,并计算三分类 REVEAL 2.0 评分(低、中、高危)。
- 试验注册号 ClinicalTrials.gov NCT00370214。
主要发现
- REVEAL 2.0 在该亚组中的区分度与原计算器相似(c 统计量 0.76 对 0.74)。
- REVEAL 2.0 风险分类间分离良好,并预测随访≥1 年患者的临床恶化与死亡。
- 三分类 REVEAL 2.0 评分区分度(c 统计量 0.73)高于 COMPERA(0.62)与 FPHR(0.64)。
- 与 REVEAL 2.0 相比,COMPERA 与 FPHR 均存在风险低估和高估。
关键数值与推荐
- REVEAL 2.0 区分度 c 统计量为 0.76,原计算器为 0.74。
- 三分类 REVEAL 2.0 评分 c 统计量为 0.73,COMPERA 为 0.62,FPHR 为 0.64。
- 生存评估时点为基线后 12 个月,基线为入组后生存≥1 年时点。
临床怎么用
- 对肺动脉高压患者可用 REVEAL 2.0 计算风险评分,按低、中、高危分层评估预后。
- 在 REVEAL 2.0 经外部验证后,可结合个体风险特征辅助治疗决策。
- 与 COMPERA、FPHR 相比,REVEAL 2.0 在本队列中风险区分更佳,选择策略时需考虑其来源人群。
局限性
- 分析基于美国 REVEAL 登记中生存≥1 年的亚组人群,非全部入组患者。
- REVEAL 2.0 尚需外部验证后才能广泛用于临床治疗决策。
- 与 COMPERA、FPHR 的比较为在本登记人群内进行,非独立外部人群头对头验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension is a progressive, fatal disease. Published treatment guidelines recommend treatment escalation on the basis of regular patient assessment with the goal of achieving or maintaining low-risk status. Various strategies are available to determine risk status. This analysis describes an update of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator (REVEAL 2.0) and compares it with recently published European Society of Cardiology/Respiratory Society guideline-derived risk assessment strategies. METHODS: A subpopulation from the US-based registry REVEAL that survived ≥ 1 year postenrollment (baseline for this cohort) was analyzed. For REVEAL 2.0, point values and cutpoints were reassessed, and new variables were evaluated. The Kaplan-Meier method was used to estimate survival at 12 months postbaseline; discrimination was quantified using the c-statistic. Mortality estimates and discrimination were compared between REVEAL 2.0 and Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) and French Pulmonary Hypertension Registry (FPHR) risk assessment strategies. For this comparison, a three-category REVEAL 2.0 score was computed in which patients were classified as low-, intermediate-, or high-risk. RESULTS: REVEAL 2.0 demonstrated similar discrimination as the original calculator in this subpopulation (c-statistic = 0.76 vs 0.74), provided excellent separation of risk among the risk categories, and predicted clinical worsening as well as mortality in patients who were followed ≥ 1 year. The REVEAL 2.0 three-category score had greater discrimination (c-statistic = 0.73) than COMPERA (c-statistic = 0.62) or FPHR (c-statistic = 0.64). Compared with REVEAL 2.0, COMPERA and FPHR both underestimated and overestimated risk. CONCLUSIONS: REVEAL 2.0 demonstrates greater risk discrimination than the COMPERA and FPHR risk assessment strategies in patients enrolled in REVEAL. After external validation, the REVEAL 2.0 calculator can assist clinicians and patients in making informed treatment decisions on the basis of individual risk profiles. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT00370214; URL: www.clinicaltrials.gov.
引用
- Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019. PMID: 30772387. doi:10.1016/j.chest.2019.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。